Trials / Completed
CompletedNCT02233686
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD
A Double-blind, Randomised, Placebo-controlled, Crossover Study to Assess the Efficacy of XEN-D0501, a Transient Receptor Potential Vanilloid Receptor 1 (TRPV1) Antagonist, in Reducing the Frequency of Cough in Patients With Chronic Obstructive Pulmonary Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Xention Ltd · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic obstructive pulmonary disease (COPD). The effectiveness of XEN-D0501 placebo in reducing capsaicin cough responses, objective 24-hour cough frequency, hourly change in cough frequency, cough severity (via visual analogue scale \[VAS\]), urge to cough (via VAS), global rating of change scale, Clinical COPD Questionnaire (CCQ), Leicester Cough Questionnaire (LCQ), and St George's Respiratory Questionnaire (SGRQ-C) will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XEN-D0501 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2014-09-08
- Last updated
- 2015-07-15
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02233686. Inclusion in this directory is not an endorsement.